Webster K. Cavenee

Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189.

Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.

In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.

Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1.

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.

Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.

Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Genetics and new approaches to cancer therapy.

A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression.

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Preparing for serendipity.

A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.

The recessive nature of dominance.

Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification.

Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.

Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor.

PTEN: a novel anti-oncogenic function independent of phosphatase activity.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

PCAF modulates PTEN activity.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Malignant astrocytic glioma: genetics, biology, and paths to treatment.

PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs.

Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor.

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.

Escape from targeted inhibition: the dark side of kinase inhibitor therapy.

Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.

KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

mTORC2 dictates Warburg effect and drug resistance.

mTORC2 in the center of cancer metabolic reprogramming.

Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation.

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Cancer metabolism as a central driving force of glioma pathogenesis.

mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.

Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.

Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.

Going viral? Linking the etiology of human prostate cancer to the long noncoding RNA and oncogenic viruses.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.